The mutant form of IDH1 acts as an oncogene to promote iCCA development by blocking cell differentiation and suppressing anti-tumor immunity.3 The high-throughput screening was conducted on 1912 oncology-focused compounds against two IDH1 mutant iCCA and two IDH1 wild-type cell lines. This evidence concerns the gene IDH1 and infantile convulsions and choreoathetosis.